Home › Funds › TCG Crossover Management, LLC › TRDA

TCG Crossover Management, LLC position in TRDA

ENTRADA THERAPEUTICS INC · Health Care

TCG Crossover Management, LLC reported holding 1,060,230 shares of TRDA (ENTRADA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.7M, representing 0.19% of its reported portfolio and ranking #44 among its reported holdings. TCG Crossover Management, LLC has disclosed TRDA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.06M sh
Reported value held$6.73M
Portfolio Weight0.19%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How TCG Crossover Management, LLC's TRDA position evolved

TCG Crossover Management, LLC first disclosed a stake in TRDA in Q3 2023 at 584,955 shares (US$9.2M). The position peaked in Q1 2026 at 2,287,500 shares, worth US$28.9M. Across 13 filings, TCG Crossover Management, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 1,060,230 shares valued at US$6.7M. Notable position changes include a 257% increase in Q4 2025 (shares rose 23% over the following quarter), a 54% trim in Q2 2026 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 584.96K $9.24M New
Q4 2023 584.96K $8.83M Hold
Q1 2024 584.96K $8.29M Hold
Q2 2024 584.96K $8.34M Hold
Q3 2024 584.96K $9.35M Hold
Q4 2024 584.96K $10.11M Hold
Q1 2025 584.96K $5.29M Hold
Q2 2025 584.96K $3.93M Hold
Q3 2025 584.96K $3.39M Hold
Q4 2025 2.09M $21.47M Add
Q1 2026 2.29M $28.87M Add
Q2 2026 1.06M $7.80M Reduce
Q3 2026 1.06M $6.73M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRDA and 13F data

TRDA (ENTRADA THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in TRDA — the largest reported positions include BAKER BROS. ADVISORS LP (US$37.3M), 5AM Venture Management, LLC (US$29.9M), Merck & Co., Inc. (US$11.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRDA

All TRDA fund holders →

FAQ

How long has TCG Crossover Management, LLC held TRDA?

TCG Crossover Management, LLC has disclosed TRDA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is TCG Crossover Management, LLC's current position in TRDA?

As of Q3 2026, TCG Crossover Management, LLC holds 1.06M shares of TRDA (ENTRADA THERAPEUTICS INC), valued at $6.73M, representing 0.19% of its reported portfolio and ranking #44.

Has TCG Crossover Management, LLC been buying or selling TRDA?

In the latest 13F filing (Q3 2026), TCG Crossover Management, LLC held unchanged its position in TRDA. The position peaked in Q1 2026 at 2.29M shares.

Which other funds hold TRDA?

Other major institutional holders of TRDA include BAKER BROS. ADVISORS LP, 5AM Venture Management, LLC, Merck & Co., Inc., among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.